Metabolism of NNK Among African Americans
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 161
- Registration Number
- NCT01158456
- Locations
- 🇺🇸
Tobacco Research Programs University of Minnesota, Minneapolis, Minnesota, United States
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer
Not Applicable
Terminated
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Carcinoma
- Interventions
- Drug: Hyperthermic intraperitoneal chemotherapy with CarboplatinOther: Isotonic saline (perfusate)Procedure: Surgery
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 10
- Registration Number
- NCT01144442
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Phase 2
Terminated
- Conditions
- Leukemia, Myelogenous, Acute
- Interventions
- Biological: Natural Killer CellsProcedure: Donor lymphapheresis
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT01106950
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Ovarian CancerFallopian Tube CancerBreast CancerPrimary Peritoneal Cancer
- Interventions
- Biological: Natural killer cells
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 13
- Registration Number
- NCT01105650
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Phase 1
Completed
- Conditions
- Cancer of the LiverHepatomaLiver CancerBiliary CancerLiver Neoplasms
- Interventions
- Biological: Salmonella typhimurium
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT01099631
- Locations
- 🇺🇸
Edward W. Greeno, MD, Minneapolis, Minnesota, United States
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT01056601
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Phase 2
Completed
- Conditions
- Hurler SyndromeHunter SyndromeSly SyndromeAlpha MannosidosisKrabbe DiseasePeroxisomal DisordersAspartylglucosaminuriaSphingolipidosesAdrenoleukodystrophy (ALD)Maroteaux-Lamy Syndrome
- Interventions
- Procedure: Allogeneic stem cell transplantation
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 46
- Registration Number
- NCT01043640
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
Phase 1
Completed
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: Myeloablative BusulfanProcedure: Mesenchymal stem cell transplantationProcedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantationRadiation: Total body irradiation
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 32
- Registration Number
- NCT01033552
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase 1
Terminated
- Conditions
- Breast CancerLung CancerColon CancerPancreatic CancerHead and Neck CancerKidney CancerSarcomaHepatocellular Cancer
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 31
- Registration Number
- NCT01012362
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Procedure: therapeutic conventional surgery
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 28
- Registration Number
- NCT01009437
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸The Kimmel Cancer Center at Jefferson University, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath